Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humans

Nutrition Journal

Bruce P Burnett¹  Victoria S Jasion¹ 

[1] Department of Medical Affairs, Entera Health, 2000 Regency Parkway, Suite 255, Cary 27518, NC, USA

关键词: Oral immunoglobulin;    Immunoglobulin digestion;    Serum-derived human immunoglobulin;    Bovine colostrum;    Serum-derived bovine immunoglobulin;   

Others  :  1139691
DOI  :  10.1186/s12937-015-0010-7

 received in 2014-12-01, accepted in 2015-02-13,  发布年份 2015

【 摘 要 】

Oral immunoglobulin (Ig) preparations are prime examples of medicinal nutrition from natural sources. Plasma products containing Ig have been used for decades in animal feed for intestinal disorders to mitigate the damaging effects of early weaning. These preparations reduce overall mortality and increase feed utilization in various animal species leading to improved growth. Oral administration of Ig preparations from human serum as well as bovine colostrum and serum have been tested and proven to be safe as well as effective in human clinical trials for a variety of enteric microbial infections and other conditions which cause diarrhea. In infants, children, and adults, the amount of intact IgG recovered in stool ranges from trace amounts up to 25% of the original amount ingested. It is generally understood that IgG can only bind to antigens within the GI tract if the Fab structure is intact and has not been completely denatured through acidic pH or digestive proteolytic enzymes. This is a comprehensive review of human studies regarding the survivability of orally-administered Ig preparations, with a focus on IgG. This review also highlights various biochemical studies on IgG which potentially explain which structural elements are responsible for increased stability against digestion.

【 授权许可】

   
2015 Jasion and Burnett; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Weiner C, Pan Q, Hurtig M, Boren T, Bostwick E, Hammarstrom L: Passive immunity against human pathogens using bovine antibodies. Clin Exp Immunol 1999, 116:193-205.
• [2]Hurley WL, Theil PK: Perspectives on immunoglobulins in colostrum and milk. Nutrients 2011, 3:442-74.
• [3]Godden SM, Smith S, Feirtag JM, Green LR, Wells SJ, Fetrow JP: Effect of on-farm commercial batch pasteurization of colostrum on colostrum and serum immunoglobulin concentrations in dairy calves. J Dairy Sci 2003, 86:1503-12.
• [4]Roos N, Mahe S, Benamouzig R, Sick H, Rautureau J, Tome D: 15 N-labeled immunoglobulins from bovine colostrum are partially resistant to digestion in human intestine. J Nutr 1995, 125:1238-44.
• [5]Kelly CP, Chetham S, Keates S, Bostwick EF, Roush AM, Castagliuolo I, et al.: Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother 1997, 41:236-41.
• [6]Warny M, Fatimi A, Bostwick EF, Laine DC, Lebel F, LaMont JT, et al.: Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 1999, 44:212-7.
• [7]Bhol KC, Tracey DE, Lemos BR, Lyng GD, Erlich EC, Keane DM, et al.: AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease. Inflamm Bowel Dis 2013, 19:2273-81.
• [8]Petschow BW, Burnett BP, Shaw AL, Weaver EM, Klein GL: Dietary Requirement for Serum-Derived Bovine Immunoglobulins in the Clinical Management of Patients with Enteropathy. Dig Dis Sci 2015, 60:13-23.
• [9]Zinkernagel RM, Hilpert H, Gerber H: The digestion of colostral bovine immunoglobulins in infants. Experientia 1972, 28:741.
• [10]Blum PM, Phelps DL, Ank BJ, Krantman HJ, Stiehm ER: Survival of oral human immune serum globulin in the gastrointestinal tract of low birth weight infants. Pediatr Res 1981, 15:1256-60.
• [11]Eibl MM, Wolf HM, Furnkranz H, Rosenkranz A: Prevention of necrotizing enterocolitis in low-birth-weight infants by IgA-IgG feeding. N Engl J Med 1988, 319:1-7.
• [12]Hilpert H, Brussow H, Mietens C, Sidoti J, Lerner L, Werchau H: Use of bovine milk concentrate containing antibody to rotavirus to treat rotavirus gastroenteritis in infants. J Infect Dis 1987, 156:158-66.
• [13]Losonsky GA, Johnson JP, Winkelstein JA, Yolken RH: Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis. J Clin Invest 1985, 76:2362-7.
• [14]Pacyna J, Siwek K, Terry SJ, Roberton ES, Johnson RB, Davidson GP: Survival of rotavirus antibody activity derived from bovine colostrum after passage through the human gastrointestinal tract. J Pediatr Gastroenterol Nutr 2001, 32:162-7.
• [15]Turner MW, Bennich HH, Natvig JB: Pepsin digestion of human G-myeloma proteins of different subclasses. II. Immunochemical investigations of the products of peptic digestion. Clin Exp Immunol 1970, 7:627-40.
• [16]Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R: Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am J Trop Med Hyg 1992, 47:276-83.
• [17]McClead RE Jr, Butler T, Rabbani GH: Orally administered bovine colostral anti-cholera toxin antibodies: results of two clinical trials. Am J Med 1988, 85:811-6.
• [18]Copelan EA, Bechtel TP, Klein JP, Klein JL, Tutschka P, Kapoor N, et al.: Controlled trial of orally administered immunoglobulin following bone marrow transplantation. Bone Marrow Transplant 1994, 13:87-91.
• [19]Bogstedt AK, Hammarstrom L, Robertson AK: Survival of immunoglobulins from different species through the gastrointestinal tract in healthy adult volunteers: implications for human therapy. Antimicrob Agents Chemother 1997, 41:2320.
• [20]Lissner R, Thurmann PA, Merz G, Karch H: Antibody reactivity and fecal recovery of bovine immunoglobulins following oral administration of a colostrum concentrate from cows (Lactobin) to healthy volunteers. Int J Clin Pharmacol Ther 1998, 36:239-45.
• [21]Moughan P: Dietary protein quality evaluation in human nutrition: Report of an FAO Expert Consultation. http://www.fao.org/ag/humannutrition/nutrition/63158/en/: FAO; Accessed 5 January 2015.
• [22]Moughan P, Gilani S, Rutherfurd S, Tome D: The assessment of amino acid digestibility in foods for humans and including a collation of published ileal amino acid digestibility for human foods. http://www.fao.org/ag/humannutrition/nutrition/63158/en/: FAO; Accessed 5 January 2015.
• [23]Goto Y, Hamaguchi K: The role of the intrachain disulfide bond in the conformation and stability of the constant fragment of the immunoglobulin light chain. J Biochem 1979, 86:1433-41.
• [24]Goto Y, Hamaguchi K: Unfolding and refolding of the reduced constant fragment of the immunoglobulin light chain. Kinetic role of the intrachain disulfide bond. J Mol Biol 1982, 156:911-26.
• [25]Ashikari Y, Arata Y, Hamaguchi K: pH-induced unfolding of the constant fragment of the immunoglobulin light chain: effect of reduction of the intrachain disulfide bond. J Biochem 1985, 97:517-28.
• [26]Thies MJ, Talamo F, Mayer M, Bell S, Ruoppolo M, Marino G, et al.: Folding and oxidation of the antibody domain C(H) 3. J Mol Biol 2002, 319:1267-77.
• [27]Pace CN, Grimsley GR, Thomson JA, Barnett BJ: Conformational stability and activity of ribonuclease T1 with zero, one, and two intact disulfide bonds. J Biol Chem 1988, 263:11820-5.
• [28]McAuley A, Jacob J, Kolvenbach CG, Westland K, Lee HJ, Brych SR, et al.: Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody CH3 domain. Protein Sci 2008, 17:95-106.
• [29]Payne RB: The controlling effect of carbohydrate in human, rabbit and bovine immunoglobulin G on proteolysis by papin. Biochem J 1969, 111:473-8.
• [30]Youings A, Chang SC, Dwek RA, Scragg IG: Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. Biochem J 1996, 314(Pt 2):621-30.
• [31]Krapp S, Mimura Y, Jefferis R, Huber R, Sondermann P: Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. J Mol Biol 2003, 325:979-89.
• [32]Zheng K, Bantog C, Bayer R: The impact of glycosylation on monoclonal antibody conformation and stability. MAb 2011, 3:568-76.
• [33]Welfle K, Misselwitz R, Hausdorf G, Hohne W, Welfle H: Conformation, pH-induced conformational changes, and thermal unfolding of anti-p24 (HIV-1) monoclonal antibody CB4-1 and its Fab and Fc fragments. Biochim Biophys Acta 1999, 1431:120-31.
• [34]Sathya Devi V, Coleman DR, Truntzer J: Thermal unfolding curves of high concentration bovine IgG measured by FTIR spectroscopy. Protein J 2011, 30:395-403.
• [35]Li Y, Mach H, Blue JT: High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies. J Pharm Sci 2011, 100:2120-35.
• [36]Martsev SP, Kravchuk ZI, Vlasov AP: Large increase in thermal stability of the CH2 domain of rabbit IgG after acid treatment as evidenced by differential scanning calorimetry. Immunol Lett 1994, 43:149-52.
• [37]Buchner J, Renner M, Lilie H, Hinz HJ, Jaenicke R, Kiefhabel T, et al.: Alternatively folded states of an immunoglobulin. Biochemistry 1991, 30:6922-9.
• [38]Vlasov AP, Kravchuk ZI, Martsev SP: [Non-native conformational states of immunoglobulins: thermodynamic and functional analysis of rabbit IgG]. Biokhimiia 1996, 61:212-35.
• [39]Kats M, Richberg PC, Hughes DE: pH-dependent isoform transitions of a monoclonal antibody monitored by micellar electrokinetic capillary chromatography. Anal Chem 1997, 69:338-43.
• [40]Andrew SM, Titus JA: Purification of immunoglobulin G. Curr Protoc Cell Biol 2000, Chapter 16:Unit 16.13 (16.13.1 – 16.13.12).
• [41]Djoumerska I, Tchorbanov A, Pashov A, Vassilev T: The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used. Scand J Immunol 2005, 61:357-63.
• [42]Djoumerska-Alexieva IK, Dimitrov JD, Voynova EN, Lacroix-Desmazes S, Kaveri SV, Vassilev TL: Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis. Febs J 2010, 277:3039-50.
• [43]McMahon MJ, O’Kennedy R: Polyreactivity as an acquired artefact, rather than a physiologic property, of antibodies: evidence that monoreactive antibodies may gain the ability to bind to multiple antigens after exposure to low pH. J Immunol Methods 2000, 241:1-10.
• [44]Porter RR: The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. Biochem J 1959, 73:119-26.
• [45]Porter RR: Chemical structure of gamma-globulin and antibodies. Br Med Bull 1963, 19:197-201.
• [46]Edelman GM, Benacerraf B, Ovary Z, Poulik MD: Structural differences among antibodies of different specificities. Proc Natl Acad Sci U S A 1961, 47:1751-8.
• [47]Edelman GM, Poulik MD: Studies on structural units of the gamma-globulins. J Exp Med 1961, 113:861-84.
• [48]Utsumi S: Stepwise cleavage of rabbit immunoglobulin G by papain and isolation of four types of biologically active Fc fragments. Biochem J 1969, 112:343-55.
• [49]Whitcomb DC, Lowe ME: Human pancreatic digestive enzymes. Dig Dis Sci 2007, 52:1-17.
• [50]Butler JE, Kennedy N: The differential enzyme susceptibility of bovine immunoglobulin G1 and immunoglobulin G2 to pepsin and papain. Biochim Biophys Acta 1978, 535:125-37.
• [51]Fang WD, Mukkur TK: Physiochemical characterization of proteolytic cleavage fragments of bovine colostral immunoglobulin G1 (IgG1). Biochem J 1976, 155:25-30.
• [52]Wie SI, Dorrington KJ, Froese A: Characterization of the proteolytic fragments of bovine colostral IgG1. J Immunol 1978, 121:98-104.
• [53]de Rham O, Isliker H: Proteolysis of bovine immunoglobulins. Int Arch Allergy Appl Immunol 1977, 55:61-9.
• [54]Reilly RM, Domingo R, Sandhu J: Oral delivery of antibodies. Future pharmacokinetic trends. Clin Pharmacokinet 1997, 32:313-23.
• [55]Petschow BW, Burnett B, Shaw AL, Weaver EM, Klein GL: Serum-derived bovine immunoglobulin/protein isolate: postulated mechanism of action for management of enteropathy. Clin Exp Gastroenterol 2014, 7:181-90.
• [56]Bosi P, Casini L, Finamore A, Cremokolini C, Merialdi G, Trevisi P, et al.: Spray-dried plasma improves growth performance and reduces inflammatory status of weaned pigs challenged with enterotoxigenic Escherichia coli K88. J Anim Sci 2004, 82:1764-72.
• [57]Perez-Bosque A, Miro L, Polo J, Russell L, Campbell J, Weaver E, et al.: Dietary plasma protein supplements prevent the release of mucosal proinflammatory mediators in intestinal inflammation in rats. J Nutr 2010, 140:25-30.
• [58]Perez-Bosque A, Amat C, Polo J, Campbell JM, Crenshaw J, Russell L, et al.: Spray-dried animal plasma prevents the effects of Staphylococcus aureus enterotoxin B on intestinal barrier function in weaned rats. J Nutr 2006, 136:2838-43.
• [59]Asmuth DM, Ma ZM, Albanese A, Sandler NG, Devaraj S, Knight TH, et al.: Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. AIDS 2013, 27:2207-17.
• [60]Torrallardona D: Spray dried animal plasma as an alternative to antibiotics in weanling pigs - a review -. Asian-Aust J Anim Sci 2010, 23:131-48.
• [61]Wilson D, Evans M, Weaver E, Shaw AL, Klein GL: Evaluation of serum-derived bovine immunoglobulin protein isolate in subjects with diarrhea-predominant irritable bowel syndrome. Clin Med Insights Gastroenterol 2013, 6:49-60.